AstraZeneca invests $2 billion in Summit Therapeutics for 12% stake
SMMT•AstraZeneca completed a $2 billion equity investment in Summit Therapeutics, giving it rights equivalent to approximately 12% of Summit's outstanding common stock, or 10.6% on a fully diluted basis. The companies also entered clinical collaborations to evaluate two drugs with Summit's ivonescimab.
1. Investment and collaborations
AstraZeneca completed the $2 billion equity investment on October 5, 2026, paying the full amount at closing. The investment gives AstraZeneca rights equivalent to approximately 12% of Summit Therapeutics' outstanding common stock, or 10.6% on a fully diluted basis. The companies entered clinical collaborations to evaluate sonesitatug vedotin and Datroway in combination with Summit's ivonescimab.
